Earlier this year, Congress passed a Big Pharma-supported policy as a rider in
a larger legislative package without having the right information on the brand
name prescription drugs that would be impacted — or the true cost to American
seniors and taxpayers.





 



DOSE OF REALITY: CONGRESS MUST REPEAL BIG PHARMA’S BLOCKBUSTER BAILOUT THAT
WILL COST SENIORS AND TAXPAYERS BILLIONS OF DOLLARS IN PREVIOUSLY
UNDERESTIMATED COSTS

ORPHAN Cures Act Will Enable Big Pharma to Keep Drug Prices High on Top Money
Makers



Earlier this year, Congress passed a Big Pharma-supported policy as a rider in
a larger legislative packagewithout having the right information on the brand
name prescription drugs that would be impacted — or the true cost to American
seniors and taxpayers. Subsequent analysis has confirmed the policy would help
Big Pharma keep prices high on some of their biggest blockbuster money makers,
amounting to a massive bailout for brand name drug companies at the expense of
billions of dollars in previously underestimated costs for the American people.



Congress did not have that information at the time the rider was passed into
law.As the true impact of this pharma-backed policy comes to light, lawmakers
must remedy the situation by repealing the Big Pharma bailout on blockbuster
brand name drugs.



Big Pharma argued the policy, known as “The Optimizing Research Progress Hope
And New (ORPHAN) Cures Act,” would help protect and foster pharmaceutical
innovation for medications with small patient populations. The truth is, this
misguided law will help brand name drug manufacturers keep prices high on a
whole category of products and cost seniors and taxpayers far more than
previously estimated.



Originally reported by The Wall Street Journal
<[link removed]>
, the nonpartisan Congressional Budget Office (CBO) previously estimated this
pharma-backed policy would cost seniors and taxpayers $4.8 billion in higher
prescription drug spending, but “[t]he true tally of the new provisions could
be far higher because CBO missed certain drugs such as Keytruda. The office
plans to re-evaluate its analysis.”



The Journal noted “Keytruda, which is used to treat cancer and had $17.9
billion in U.S. sales in 2024.” The report also identified Johnson and Johnson
product “Darzalex, a melanoma treatment, is estimated to have had $5.6 billion
in gross Medicare spending last year… Bristol-Myers Squibb’s cancer drugs
Opdivo and Yervoy, which are estimated to have cost Medicare $4.7 billion and
$993 million, respectively, in 2024… [and] AbbVie’s blood-cancer pill
Venclexta, is estimated to have had $814 million in gross Medicare spending in
2024,” as additional blockbuster brand name medications that would become
exempt from solutions designed to lower drug prices for seniors and taxpayers
under the provisions.



Multiple subsequent analyses shed further light on the breadth of blockbuster
brand name drugs that may be impacted by the policy,which
<[link removed]>
“will likely mean higher out-of-pocket costs for Medicare beneficiaries who
use these medications.”



According to an analysis
<[link removed]>
published in Health Affairs in August by Jennifer C. Chen and Anna Kaltenboeck
of Verdant Research, there are at least 10 brand name drugs that could be
impacted by the recently passed Big Pharma-backed provision. Their analysis
includes several products not previously thought to be impacted, including
Incyte’s immunomodulator and oncology drug Jakafi, Teva’s tardive dyskinesia
drug Austedo and Exelixis’ cancer drug Cometriq. According to this analysis,
gross Medicare spending on these drugs in 2023 amounted to $13.8 billion, and
nine of the 10 drugs that could be impacted are for certain forms of cancer.



A second analysis
<[link removed]>
in Health Affairs also published in August by researchers associated with The
University of Washington’s School of Pharmacy, identified at least 13 brand
name drugs that could be impacted by the ORPHAN Cures Act. These 13 drugs,
between Medicare Part B and Medicare Part D, had projected gross spending of
over $33 billion in 2024. Additional brand name drugs included in this analysis
include AbbVie’s cancer drug Venclexta, Novartis’ multiple sclerosis drug
Kesimpta and Pfizer’s cancer drug Adcetris.



Another analysis
<[link removed]>
on the impact of the ORPHAN Cures Act from Kaiser Family Foundation (KFF)
found at least 18 brand name drugs that could be impacted by the provision.
These 18 drugs combined for $17.5 billion in Medicare spending in 2023.



Keytruda: A Case Study in Big Pharma’s Blockbuster Greed



Keytruda generated $8 billion in sales for its brand name manufacturer Merck
in the second quarter of this year alone. This blockbuster, now projected to be
impacted by ORPHAN Cures, provides a case study in Big Pharma’s egregious
pricing and anti-competitive practices. Already patent-protected in the U.S.
until 2028, Merck is working to further extend monopoly pricing and undermine
competition from more affordable alternatives beyond 2028 by seeking a new
formulation and additional patents. At the J.P. Morgan Healthcare Conference in
January 2025, Merck CEO Rob Davissaid
<[link removed]>
the brand name drug company is “moving up plans to file for approval and
launch a subcutaneous version of Keytruda by the end of 2025.”



According to research
<[link removed]>
from I-MAK, Merck has filed for 129 patent applications on Keytruda – more
than half of which were filed after the drug’s initial approval by the U.S.
Food and Drug Administration (FDA). The Big Pharma company has been granted 53
patents on this one drug. I-MAK estimates that Americans will spend at least
$137 billion on Keytruda while the drug faces no competition due to its
extended exclusivity that already totals more than eight years — without
reflecting the added impact of the Big Pharma giant’s new patent strategy.


 

As the full impact of the Big Pharma bailout for high-priced blockbuster drugs
comes to light, Congress should act to protect seniors and taxpayers from
billions of dollars in higher prescription drug costs by repealing the ORPHAN
Cures Act.



Read the full report in The Wall Street Journal HERE
<[link removed]>
.



Read the Health Affairs analyses on the ORPHAN Cures Act HERE
<[link removed]>
andHERE
<[link removed]>
.



Read KFF’s analysis of the impact of the ORPHAN Cures Act HERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>